Last reviewed · How we verify
vena punction
At a glance
| Generic name | vena punction |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study (NA)
- TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects
- The GALLOP-11 Study
- The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
- Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
- Antibodies Causing Epilepsy Syndromes: The ACES Study.
- In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides
- PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vena punction CI brief — competitive landscape report
- vena punction updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI